US Patent Family Members and Approved Drugs for Denmark Patent: 2270052

✉ Email this page to a colleague

US Patent Family Members and Approved Drugs for Denmark Patent: DK2270052

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.

Glossary

Subscribe to access the full database, or Start Trial
US Patent Number	Estimated Patent Expiration	Generic Name	US Applicant	US Tradename
⤷ Start Trial	2021-06-26	denosumab	Amgen, Inc.	PROLIA
⤷ Start Trial	2021-06-26	denosumab	Amgen, Inc.	PROLIA
⤷ Start Trial	2021-06-26	denosumab	Amgen, Inc.	PROLIA
>US Patent Number	>Estimated Patent Expiration	>Generic Name	>US Applicant	>US Tradename

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.